Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Adicet Bio Inc.

    NASDAQ: ACET · Real-Time Price · USD
    0.71
    -0.01 (-0.84%)
    At close: Jun 17, 2025, 10:51 AM
    -0.84%
    Bid 0.71
    Market Cap 58.6M
    Revenue (ttm) n/a
    Net Income (ttm) -117.32M
    EPS (ttm) -1.29
    PE Ratio (ttm) -0.55
    Forward PE -0.87
    Analyst Buy
    Ask 0.72
    Volume 61,711
    Avg. Volume (20D) 538,714
    Open 0.73
    Previous Close 0.72
    Day's Range 0.70 - 0.74
    52-Week Range 0.45 - 1.70
    Beta 1.66

    About ACET

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ACET
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ACET stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -18.65%
    Adicet Bio shares are tracing lower. The company r... Unlock content with Pro Subscription
    4 months ago
    +9.79%
    Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.
    news image

    3 weeks ago · businesswire.com

    Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    1 month ago · zacks.com

    Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

    Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · businesswire.com

    Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    1 month ago · businesswire.com

    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    1 month ago · businesswire.com

    Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    2 months ago · businesswire.com

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    2 months ago · businesswire.com

    Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    2 months ago · businesswire.com

    Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    Add to Watchlist